Side Effects With Sorafenib More Pronounced in Thyroid CancerSide Effects With Sorafenib More Pronounced in Thyroid Cancer

The incidence of side effects from the oral multikinase inhibitor sorafenib appears to be considerably higher among patients with differentiated thyroid cancer than those with renal cell or hepatocellular carcinoma. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news